These new software offerings are still in development, but that work is happening in parallel with the growing industry adoption of decentralized clinical trials. The latest SignalPath financing was raised in part to support the company’s move into providing the tools that enable study sponsors to conduct hybrid clinical trials -studies that bridge traditional in-person studies with virtual trials.
According to securities filings, the startup has raised nearly $34 million, most recently an $18 million Series B round of funding in 2019.
SignalPath, co-founded in 2014 by CEO Brad Hirsch, developed a clinical trial management system that later evolved to address other aspects of clinical research, such as study design and oversight of site management organizations. The software also captures real-world and self-reported data, and it supports continued engagement with study investigators by enabling video visits.
The technology’s features include the capability of prescreening study participants and providing electronic consent. The software platform the company developed to gather these insights was named Baseline.
Verily’s efforts began in 2017 with Project Baseline, a longitudinal study aiming to enroll 10,000 volunteers, tracking them over time to gain insights about health and disease.